Sanofi reported that its Phase 3 trial for amlitelimab, an anti-OX40L antibody for atopic dermatitis, successfully met primary and key secondary endpoints including skin clearance and disease severity reduction. However, the data failed to replicate the strong Phase 2 results, falling short of analyst expectations and causing the company’s shares to drop approximately 9%. This outcome raises concerns about the viability of this drug class within immunology. Sanofi continues its push in dermatology and immunology despite the setback.